Nephrogen
Curative genetic medicines for kidney diseases
Community-submitted · content unverified. This organization has not verified ownership or the information in this profile.
About
Nephrogen is a Stanford biotech spin-out developing curative genetic medicines for kidney and pancreatic diseases. Kidney disease alone affects 1 in 7 Americans, and neither indication has any approved gene-based therapies. Nephrogen's underlying platform combines AI and high-throughput screening to engineer safer, more efficient, and less expensive gene delivery vehicles for reaching the kidney and pancreas, and has attracted non-dilutive funding from seven major pharmaceutical companies including Merck KGaA, Novartis, and Bristol Myers Squibb. Nephrogen is a Y Combinator company (Summer 2020). YC-listed status: Active.
- Website
- nephrogenbiotech.com
- Location
- New York City, NY, USA
- Added via
- web
- Ownership
- unclaimed
Where to go
Products
- Nephrogen — AI and high-throughput in vivo screening platform (NeFIND) that engineers AAV delivery vehicles 10–100x more efficient for kidney and pancreatic gene therapy. · Other · Enterprise
Links
- Y Combinator profileycombinator